NV
Novacyt S.A.
NVYTF · OTC
$0.57 -0.09% (-$0.00)
Market Cap £31.0M
P/E Ratio -
Div. Yield -
ROE 96.86%
Bulios Fair Price
$0.31
45.7% downside
Current Price
$0.57
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NVYTF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
99 /100
Cheap P/B 1.33x
P/S 1.23x
EV/FFO N/A
Growth
12 /100
Declining Book val. growth 41.29%
Rev. growth 1.04%
FCF growth N/A
Profitability
20 /100
Weak Net margin 123.80%
Op. margin 96.16%
FCF margin 43.29%
Quality
8 /100
Poor ROE 96.86%
ROA 77.60%
Asset turnover 0.63x
Debt
64 /100
Moderate Current ratio 4.74x
Int. coverage -23.42x
Debt/Equity 0.45x
Stability
31 /100
Unstable Rev. volatility 57.46%
EPS volatility 48.42%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NVYTF
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Lyn Dafydd Rees
Employees
234
Headquarters
Le Vésinet
Upcoming events
24 SEP
Earnings
Upcoming earnings report